Wainua.ca | TTR Suppression Data

EN FR

WAINUA^®

WAINUA reduced serum TTR concentrations as early as Week 5, with a significant difference in the change from baseline vs. external placebo at Week 35 (when steady state was reached) and through Week 65 (p<0.001; pharmacodynamic endpoint)^1,2

Change in serum TTR concentration through 65 weeks^1,2^†

LSM % change from baseline at Week 35 (interim analysis): 81.1% WAINUA vs. -14.5% external placebo (difference: -66.6%; p<0.001)
LSM % change from baseline at Week 65 (final analysis): -81.6% WAINUA vs. -11.2% external placebo (difference: -70.4%; 95% CI: -75.2, -65.7; p<0.001)

Adapted from the WAINUA Product Monograph and Coelho T, et al.^1,2
† Following baseline, external placebo was assessed at Weeks 5, 8, 13, 23, 35, 47, 59, and 65, while WAINUA was assessed at Weeks 5, 9, 13, 25, 35, 49, 57, and 65.²

TTR reduction sustained up to Week 85 with WAINUA.¹

See NEURO-TTRansform trial design

TTR: transthyretin; LSM: least squares mean; CI: confidence interval.

* Clinical significance unknown.

References: 1. WAINUA® Product Monograph. AstraZeneca Canada Inc. August 26, 2025. 2. Coelho T, Marques Jr W, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448-1458.

WAINUA® Important Safety Information

WAINUA®

TTR Suppression Data*

WAINUA reduced serum TTR concentrations as early as Week 5, with a significant difference in the change from baseline vs. external placebo at Week 35 (when steady state was reached) and through Week 65 (p<0.001; pharmacodynamic endpoint)1,2

AZ Reg Popup

Sign up for AstraZeneca mail

WAINUA^® Important Safety Information

WAINUA^®

WAINUA reduced serum TTR concentrations as early as Week 5, with a significant difference in the change from baseline vs. external placebo at Week 35 (when steady state was reached) and through Week 65 (p<0.001; pharmacodynamic endpoint)^1,2